Biobanking Program


Board

Pr. Benoît Terris
Physician – Pathologist
Dr. Marie-Alexandra Alyanakian
Physician – Immunologist
Dr. Benoît Védie
Biochemist


Steering Committee

Pr. Thierry Molina - Pathologist
Pr. CaCécile Badoual - Pathologist
Pr. Vahid Asnafi - Haematobiologist
Pr. Michaela Fontenay - Haematobiologist
Pr. Hélène Blons - Biologist
Dr. Béatrice Romagnolo - Scientist

The Biobank Program is part of the PARIS CANCER INSTITUTE: CARPEM. This program aims to foster partnerships/collaborations for Cancer Research by providing French and International researchers with access to high quality human biological samples in compliance with French and European regulations. To achieve these objectives, the federation of the three biobanks entitled Necker Biobank (Biological Resources Platform), Georges Pompidou Biobank (Biological Resources Platform) and Cochin Biobank (Biological Resources Centre) were created within the SIRIC CARPEM. They put their efforts together to collect, store, characterise and distribute human biological samples for cancer research purpose. Three types of human biological samples are stored in these banks:
  • Biological fluid samples including plasma, serum, faeces, urine, DNA and RNA. These samples come from the clinical departments of the hospital.
  • Cells (lymphoblastoid cell lines, EBV-transformed, DMSO conserved and cell pellets and others). Most of the cellular samples (Peripheral Blood Mononuclear and Bone Marrow cells) come from the haematological diagnostic activities.
  • Tissue samples, originating from clinical and surgical activities from different hospital departments (digestive, urological, thoracic …).
In addition, the three pathology departments collect and store routinely a great amount of paraffin-embedded tissues, which are available for researchers. From these paraffin blocks and thanks to molecular biological tools, nucleic acid extraction can be carried out to undertake genomics and proteomics projects. These blocks are also used in morphometric studies and in situ validation. These samples are cryopreserved at -80°C, -20°C or at -196°C in liquid nitrogen. Every freezer and cryogenic storage have temperature monitoring as an essential part of quality assurance. Paris Cancer Institute CARPEM Biobank is NF S 96 900 certified, which is the French standard regarding the Quality Management System (QMS) of biological samples. The scope of QMS is to improve the processing, performance and tracking of biospecimens, in order to optimize sample quality and annotations. This certification ensures that the biological resource users/researchers are satisfied with the samples provided by the Biobank. Specific software in each Biobank ensures the traceability and the security of the data. Moreover, the Biobanks operate in compliance with GDPR (General Data Protection Regulation) requirements. To ensure the confidentiality of the personal and clinical data, a unique code number is assigned to biological sample by each bank. Prior to the collection of personal and clinical data, the participants must have given their consent for research purpose. A unique informed consent for the collection and storage of biological samples for Cancer Research purpose is being implemented within the Paris Cancer Institute CARPEM biobanks. This informed consent will be then submitted to the National Ethics Committee, which ensures that the participant’s rights are fullfilled. As ethics requirements, informed consent includes:
  • The purpose of the human biological samples storage and associated data
  • The measure to maintain confidentiality of personal and medical records
  • The potential risks and benefits
  • The reference contact for any further questions
  • A statement that participation is voluntary
In order to improve the consent track, the SIRIC CARPEM has recruited three biomedical Engineers. They help medical and clinical teams regarding informed consent to solve problems that the medical staff face. To increase participant understanding and the awareness of the informed consent, the CARPEM Engineers produced various media supports (leaflets, poster and the movie called « We are all actors for the Cancer research), which are disseminated in the waiting rooms of the medical and clinical departments. In 2016, the HEGP and Cochin biobanks obtained the authorisation from the National Ethics Committee for the use of biological samples from deceased participants, justified by “non opposition” of the participant during his lifetime. These different actions have increased by three the number of biospecimens associated with consent, which now represent more than 50% of samples in some sub-specialties.

Researchers can request human biological samples trough the Biological Sample Request Form.

To complete this form, the investigator must inform:

  • The total number of samples required
  • The type of sample requested
  • A research summary
  • Proof of ethics approval for the project

The Biobank Manager reviews the enquiry and then submits the application to the local Research Scientific Committee, which assesses the relevance and the feasibility of the project and validates the use of biological samples for the research project. For approved applications, all researchers involved in the project and their institution must sign a Material Transfer Agreement prior to the supply of samples.

Today, close to 264000 samples are stored in the freezers and liquid nitrogen. This priceless collection includes a diversity of biological sample nature (cell line, serum, plasma, tissue nucleic acid and so on) originating from oncology pathologies, whose most represented are thoracic, gynaecological, urological and haematological cancers.

Thanks to Paris Cancer Institute CARPEM Biobank, more than 30 research projects have started since the beginning of the CARPEM institute.

Having a large biological sample collection, Paris Cancer Institute CARPEM Biobank set up new strategies to ease the sample access to national and international researchers: development of a website (http://carpem.fr/en/activities/platforms/biobank/), increase of industrial and academic contracts and skilled personal recruitment.

The biobanks are a key tool to promote new challenge in European research. They represent a unique combination in biomedical research, in ethical requirements, multidisciplinary and international collaboration.

More than 30 research projects have started since the beginning of the CARPEM institute. Some of them are listed below.

  • OncoHEGP: Biological samples and clinical data collection for cancer research
  • RASANC: RAS mutations in circulating blood in patients with metastatic colorectal cancer
  • AXA: XA activity in patients affected with cancer and treated with low-molecular weight heparin for venous thromboembolic disease
  • BIOVAIRE: Assessment of tumor circulating DNA amount as prognosis and predictive biomarker in advanced ovarian cancer
  • PAOLA-1: Phase III multicentre study, comparison Olaparib vs placebo in patients with advanced ovarian, fallope tube or stage FIGO IIIB-IV peritoneum cancer
  • PREINSUT: Biological, histological and imaging markers study for the treatment of metastatic renal cell carcinoma
  • ATALANTE: Phase III study, comparison Azetolizumab vs placebo in  patients affected with epithelial ovarian, or peritoneum cancer and treated with platine and Bevacizumab chemotherapy
  • OncoNEM: Biological samples and clinical data collection for cancer research
  • SPRUES (EATL type I et type II): Lymphoma and Type II resistant Coeliac Disease (the CELAC network)
  • RT3 for transcriptomic studies in Large B cell Lymphoma with the LYSA study group
  • Many studies in adult T-ALL (T Acute Lymphoblastic Leukemia) with the GRAALL Groupe de Recherche sur Acute Lymphoblastic Leukemia de l’Adulte (GRALLE, PI clinique) the SFCE (Societe Francaise des Cancers de l’Enfant) for pediatric T-ALL
  • ATL et HTLV1 viral integration.
  • ALCL (Anaplastic Large Cell lymphoma) – joint adult pediatric translational research with LYSA and SFCE.
  • Mantle Cell Lymphoma MRD follow-up protocols (EU-MCL, MCLR2, LYMA, LYMA101, OASIS II) with the LYSA and the European MCL group
  • T-Lymphoblastic lymphomas in adults and children with the GRAALL, LYSA and FRALLE
  • RELYE (Pediatric Lymphoma Network and national bank) with the SFCE
  • OncoCCH: Biological samples and clinical data collection for cancer research
  • COMETE: Translational research in tumors and hyperlasia adrenal glands and paraganglioma
  • PLEIOSARC: Prognosis biomarker identification in pleomorphic Soft-Tissue Sarcoma
  • TNE: Pancreatic Neuroendocrine Tumor molecular analysis
  • ELCAPA: Elderly Cancer Patient Cohort
  • OncoGYN: Biological samples and clinical data in gynaecological cancer
  • MDS-04: PHRC national cancer, translational research on myelodysplastic syndromes
  • Biological studies of RETACRIT, PRETAR clinical trials of the Myelodysplasia French Group (GFM, PI)
  • COMBOLA and LUSPLUS clinical trials: European translational research on sideroblastic anemia

Based on our skillness we would like to

  • Incorporating digital pathology into biobank quality assurance procedures will be developed. Using automated pattern recognition morphometric image analysis to quantify tissue feature areas in digital whole slide images of frozen tissue sections will improve reproducibility among our collections and facilitate research-relevant specimen selection. Such development will also permit to assess not only tumor heterogeneity but also the diversity and the distribution of the inflammatory cell phenotypes, which infiltrate primary and metastatic lesions.
  • Virtual Biobanking Platform: The CARPEM Biobanks aim to create a common online platform between Necker, HEGP and Cochin. This platform will assist in providing access for European researchers to high quality human biological resources hosted by the three CARPEM biobanks. The implementation of this platform demands a procedure and the use of a common software, which will further contribute to harmonisation between the different structures.
  • In the long term, our ambition is to integrate the CARPEM Biobank data in the AP-HP Clinical Data Repository, which aggregates electronic health record data of 37 hospitals to facilitate research projects.
  • The Paris Cancer Institute CARPEM Biobanks intends to promote new national and international collaborations for cancer research purpose. In order to gain in more visibility a website has been implemented and the Biobanks will increase the participation in international conferences about biobanking and oncology research.

Annex 1:  Number of collected samples

Collected, stored and
released samples for
research purpose
20172018
HEGPNeckerCochinHEGPNeckerCochin
Sample collected events156655291033158955503672
Stored samples for the year ≤ 4°C11531629953691308265249044
Transferred samples for research342951413095383546212237
Total stored samples ≤ 4°C64767111930401767161912625965916

Annex 2:  Storage equipment in Paris Cancer Institute CARPEM Biobanks

Number ofHEGPNeckerCochinTotal
Equipments at  -196°C110516
Equipments at  -80°C4,571324,5
Equipments at  -20°C010515
If you are interested by this program and want to candidate to a PhD, post doctoral position, contact the leader
Pr. Benoit Terris

Contact us

Centre Universitaire des Saints-Pères Etage 4 – Pièce 446B 45 rue des Saints-Pères -75006 Paris

Carina Binet : Secrétaire Général du CARPEM
Tél. : 01 76 53 43 85 – carina.binet@carpem.fr

Aurore Hattabi, PhD : Coordinatrice Scientifique du CARPEM
Tél : 01 76 53 43 85 – aurore.hattabi@carpem.fr

contact@carpem.fr